Bone Biologics (BBLG) Change in Account Payables (2014)
Bone Biologics (BBLG) posted quarterly Change in Account Payables of -$140175.0 for Q4 2014, down 1575.37% quarter-over-quarter from $9501.0 in Q3 2014.
Powered by 
Analysis
Bone Biologics (BBLG) Change in Account Payables (2014) Analysis & Trends
Bone Biologics (BBLG) has reported Change in Account Payables for 1 consecutive years, with -$140175.0 the latest figure, recorded in Q4 2014.
- In Q4 2014, Change in Account Payables changed N/A year-over-year to -$140175.0; the TTM figure through Dec 2014 stood at -$41300.0 (changed N/A YoY), while the FY2014 annual figure was -$41300.0, down 200.0% from the prior year.
- Change in Account Payables retreated to -$140175.0 in Q4 2014 per BBLG's latest filing, from $9501.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $89441.0 in Q1 2014 and bottomed at -$140175.0 in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | - |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2014 | -140,175.00 |
| Sep 30, 2014 | 9,501.00 |
| Jun 30, 2014 | -67.00 |
| Mar 31, 2014 | 89,441.00 |